DOI:
10.1055/s-00000173
Neuroradiologie Scan
LinksClose Window
References
Herrlinger U, Tzaridis T, Mack F. et al.
Neurooncology Working Group of the German Cancer Society: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Lancet 2019;
393: 678-688
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.